Max Signaevsky

max1

NeuroSilica, Inc.

2019-2020

Technologies

Materials

Indication

Brain-Computer Interface

Central Nervous System Disorders

Deep Brain Stimulation

Developmental Disorders

Functional Prosthetics

Neurodegenerative Disease

Neuromodulation

NeuroSilica’s objective is to develop and commercialize a novel nanotechnology–based biocompatible implantable materials for biomedical applications such as Deep Brain Stimulation and Brain-Computer Interface.

Newsletter Signup

Corporate Supporters

Community Service Providers